Grifols announces larger vial size for ALPHANATE, its factor VIII/von Willebrand factor product.
RIXUBIS (Coagulation Factor IX [Recombinant]), manufactured by Baxter International, Inc., previously approved for adults, is now FDA-approved for children with hemophilia B.
A team of researchers is using genetically engineered tobacco plants to deliver factor VIII, without causing inhibitors or anaphylaxis, a life-threatening allergic reaction.
Achillion’s ACH-3102, a new therapy for patients with hepatitis C virus (HCV), performs well in 8-week clinical trial.
Expression and ABL collaborate to provide recombinant factor VIII product that is affordable and available to people with hemophilia in the developing world.
Baxter's BAX 855, an experimental extended half-life recombinant factor VIII product, performed well in a Phase 3 clinical trial in patients with severe hemophilia A.
Pfizer’s BeneFIX® shows significantly reduced annual bleeding rates in a clinical trial comparing prophylaxis vs on-demand regimens.
The FDA approved Octapharma's Octagam ® 10% to treat chronic ITP, a platelet disorder.
The FDA approved Novo's NovoSeven RT®, the first recombinant treatment option, for people with Glanzmann's thrombasthenia, a rare clotting disorder.
Bayer HealthCare and Dimension Therapeutics will collaborate on gene therapy for hemophilia A.
eNewsletter Sign Up
Steps for Living
Victory for Women
Donate Your Car